In Ukraine many patients bought Rebif 44 in new package with note "New
formulation". It is not falsification. But what is this? How does it differ from
drugs that were produced by Merck Serono earlier? We will try to
answer these questions.

ESHRE CAMPUS SYMPOSIUM and Annual Meeting of the Ukrainian Association of Reproductive Medicine (UARM) will be held on 26-28 May, 2010 in Kiev organized by European Society of Human Reproduction and Embryology (ESHRE) together with Ukrainian Association of Reproductive Medicine and with assistance of the Ministry of Public Health of Ukraine, Ukrainian State Institute of Reproductive Medicine, National Medical Academy of Post-graduate Education named after Shupik and Sona-pharm LLC. The provident specialists from Great Britain, Germany, the Netherlands, Italy, Greece, Belgium and Russia will participate in this symposium. Theoretical and practical options for women with fertility problems will be clarified. Results in additional reproductive technologies will be reported. Sona-pharm is the General Sponsor of this symposium and it will conduct Pergoveris Launch Symposium within its' bounds. For more information, please click http://www.uarm.org.ua

A new drug Pergoveris to treat infertility is registered. Pergoveris is a combination of follitropin alfa (r-hFSH) 150 IU and lutropin alfa (r-hLH) 75 IU. Pergoveris is a highly effective, safe and easy to use drug in ART due to recombinant technology and FSH and LH optimal ratio. For more information, please click http://www.merckserono.com/en/therapeutic_areas/fertility/infertility/pergoveris/pergoveris.html